StreetInsider.com News Articles

Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement

Mon, 09 Dec 2024 01:30:00 -0400

Dijon, France, December 09, 2024, 07:30 CET – Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing the award-winning needle-free ZENEO® autoinjector to deliver life-saving medicines in emergency situations, and the U.S. Department of Defense (DOD), have relaunched their cooperative research on needle-free autoinjectors, signing an extension of their Cooperative Research and Development Agreement (CRADA) from October 2019. As part of the agreement, the DOD will evaluate an upgraded version of the company’s proprietary needle-free autoinjector ZENEO®.

“We are glad to extend our agreement with the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear

Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement

Mon, 09 Dec 2024 01:30:00 -0400

“We are glad to extend our agreement with the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear

Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement

Mon, 09 Dec 2024 01:30:00 -0400

“We are glad to extend our agreement with the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear

Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement

Mon, 09 Dec 2024 01:30:00 -0400

“We are glad to extend our agreement with the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear

Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement

Mon, 09 Dec 2024 01:30:00 -0400

“We are glad to extend our agreement with the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear

Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement

Mon, 09 Dec 2024 01:30:00 -0400

“We are glad to extend our agreement with the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear

Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement

Mon, 09 Dec 2024 01:30:00 -0400

“We are glad to extend our agreement with the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear

Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement

Mon, 09 Dec 2024 01:30:00 -0400

“We are glad to extend our agreement with the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear

Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement

Mon, 09 Dec 2024 01:30:00 -0400

“We are glad to extend our agreement with the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear

Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement

Mon, 09 Dec 2024 01:30:00 -0400

“We are glad to extend our agreement with the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear

Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Thu, 22 Aug 2024 01:30:00 -0400

Press Release

Dijon, France August 22, 2024 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO®, announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel in New York City from September 9th-11th, 2024 in New York.

Crossject’s corporate presentation will be available on-demand beginning on Monday, September 9th at 7:00 am (ET) via the conference platform. In addition, the presentation will

Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Thu, 22 Aug 2024 01:30:00 -0400

Press Release

Crossject’s corporate presentation will be available on-demand beginning on Monday, September 9th at 7:00 am (ET) via the conference platform. In addition, the presentation will

Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Thu, 22 Aug 2024 01:30:00 -0400

Press Release

Crossject’s corporate presentation will be available on-demand beginning on Monday, September 9th at 7:00 am (ET) via the conference platform. In addition, the presentation will

Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Thu, 22 Aug 2024 01:30:00 -0400

Press Release

Crossject’s corporate presentation will be available on-demand beginning on Monday, September 9th at 7:00 am (ET) via the conference platform. In addition, the presentation will

Crossject achieves key ZEPIZURE® manufacturing milestone

Thu, 18 Jul 2024 01:30:00 -0400

Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing site
Milestone complements the satisfying results from previous batches under stability studies, and is part of the positive manufacturing data generated since 2021
Manufacturing progress supports timelines toward granting of Emergency Use Authorization (EUA)

Dijon, France, July 18, 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency treatment for the management of epileptic crises based on its award-winning needle-free auto-injector ZENEO®, announces the successful completion of a

Crossject achieves key ZEPIZURE® manufacturing milestone

Thu, 18 Jul 2024 01:30:00 -0400

Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing site
Milestone complements the satisfying results from previous batches under stability studies, and is part of the positive manufacturing data generated since 2021
Manufacturing progress supports timelines toward granting of Emergency Use Authorization (EUA)

Crossject achieves key ZEPIZURE® manufacturing milestone

Thu, 18 Jul 2024 01:30:00 -0400

Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing site
Milestone complements the satisfying results from previous batches under stability studies, and is part of the positive manufacturing data generated since 2021
Manufacturing progress supports timelines toward granting of Emergency Use Authorization (EUA)

Crossject achieves key ZEPIZURE® manufacturing milestone

Thu, 18 Jul 2024 01:30:00 -0400

Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing site
Milestone complements the satisfying results from previous batches under stability studies, and is part of the positive manufacturing data generated since 2021
Manufacturing progress supports timelines toward granting of Emergency Use Authorization (EUA)

Crossject achieves key ZEPIZURE® manufacturing milestone

Thu, 18 Jul 2024 01:30:00 -0400

Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing site
Milestone complements the satisfying results from previous batches under stability studies, and is part of the positive manufacturing data generated since 2021
Manufacturing progress supports timelines toward granting of Emergency Use Authorization (EUA)

Crossject achieves key ZEPIZURE® manufacturing milestone

Thu, 18 Jul 2024 01:30:00 -0400

Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing site
Milestone complements the satisfying results from previous batches under stability studies, and is part of the positive manufacturing data generated since 2021
Manufacturing progress supports timelines toward granting of Emergency Use Authorization (EUA)

Crossject achieves key ZEPIZURE® manufacturing milestone

Thu, 18 Jul 2024 01:30:00 -0400

Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing site
Milestone complements the satisfying results from previous batches under stability studies, and is part of the positive manufacturing data generated since 2021
Manufacturing progress supports timelines toward granting of Emergency Use Authorization (EUA)

Crossject achieves key ZEPIZURE® manufacturing milestone

Thu, 18 Jul 2024 01:30:00 -0400

Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing site
Milestone complements the satisfying results from previous batches under stability studies, and is part of the positive manufacturing data generated since 2021
Manufacturing progress supports timelines toward granting of Emergency Use Authorization (EUA)